208 related articles for article (PubMed ID: 31610718)
1. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.
Essebag V; Healey JS; Joza J; Nery PB; Kalfon E; Leiria TLL; Verma A; Ayala-Paredes F; Coutu B; Sumner GL; Becker G; Philippon F; Eikelboom J; Sandhu RK; Sapp J; Leather R; Yung D; Thibault B; Simpson CS; Ahmad K; Toal S; Sturmer M; Kavanagh K; Crystal E; Wells GA; Krahn AD; Birnie DH
Circ Arrhythm Electrophysiol; 2019 Oct; 12(10):e007545. PubMed ID: 31610718
[TBL] [Abstract][Full Text] [Related]
2. Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial.
Essebag V; AlTurki A; Proietti R; Healey JS; Wells GA; Verma A; Krahn AD; Simpson CS; Ayala-Paredes F; Coutu B; Leather R; Ahmad K; Toal S; Sapp J; Sturmer M; Kavanagh K; Crystal E; Leiria TLL; Seifer C; Rinne C; Birnie D;
Int J Cardiol; 2019 Aug; 288():87-93. PubMed ID: 31056413
[TBL] [Abstract][Full Text] [Related]
3. Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection: BRUISE CONTROL INFECTION Study.
Essebag V; Verma A; Healey JS; Krahn AD; Kalfon E; Coutu B; Ayala-Paredes F; Tang AS; Sapp J; Sturmer M; Keren A; Wells GA; Birnie DH;
J Am Coll Cardiol; 2016 Mar; 67(11):1300-8. PubMed ID: 26988951
[TBL] [Abstract][Full Text] [Related]
4. Pacemaker or defibrillator surgery without interruption of anticoagulation.
Birnie DH; Healey JS; Wells GA; Verma A; Tang AS; Krahn AD; Simpson CS; Ayala-Paredes F; Coutu B; Leiria TL; Essebag V;
N Engl J Med; 2013 May; 368(22):2084-93. PubMed ID: 23659733
[TBL] [Abstract][Full Text] [Related]
5. Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Essebag V; Healey JS; Ayala-Paredes F; Kalfon E; Coutu B; Nery P; Verma A; Sapp J; Philippon F; Sandhu RK; Coyle D; Eikelboom J; Wells G; Birnie DH
Am Heart J; 2016 Mar; 173():102-7. PubMed ID: 26920602
[TBL] [Abstract][Full Text] [Related]
6. Frequency of "Pocket" Hematoma in Patients Receiving Vitamin K Antagonist and Antiplatelet Therapy at the Time of Pacemaker or Cardioverter Defibrillator Implantation (from the POCKET Study).
Malagù M; Trevisan F; Scalone A; Marcantoni L; Sammarco G; Bertini M
Am J Cardiol; 2017 Apr; 119(7):1036-1040. PubMed ID: 28153344
[TBL] [Abstract][Full Text] [Related]
7. Pocket haematoma after cardiac electronic device implantation in patients receiving antiplatelet and anticoagulant treatment: a single-centre experience.
Demir GG; Guler GB; Guler E; Güneş H; Kizilirmak F; Karaca İO; Omaygenç MO; Çakal B; Olgun E; Savur U; Ibisoglu E; Barutçu I; Kiliçaslan F
Acta Cardiol; 2017 Feb; 72(1):47-52. PubMed ID: 28597740
[TBL] [Abstract][Full Text] [Related]
8. Cardiac implantable electronic device hematomas: Risk factors and effect of prophylactic pressure bandaging.
Koh Y; Bingham NE; Law N; Le D; Mariani JA
Pacing Clin Electrophysiol; 2017 Jul; 40(7):857-867. PubMed ID: 28543543
[TBL] [Abstract][Full Text] [Related]
9. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies.
Proietti R; Porto I; Levi M; Leo A; Russo V; Kalfon E; Biondi-Zoccai G; Roux JF; Birnie DH; Essebag V
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1461-79. PubMed ID: 25967723
[TBL] [Abstract][Full Text] [Related]
10. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI).
Deharo JC; Sciaraffia E; Leclercq C; Amara W; Doering M; Bongiorni MG; Chen J; Dagres N; Estner H; Larsen TB; Johansen JB; Potpara TS; Proclemer A; Pison L; Brunet C; Blomström-Lundqvist C;
Europace; 2016 May; 18(5):778-84. PubMed ID: 27226497
[TBL] [Abstract][Full Text] [Related]
11. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
Birnie DH; Healey JS; Wells GA; Ayala-Paredes F; Coutu B; Sumner GL; Becker G; Verma A; Philippon F; Kalfon E; Eikelboom J; Sandhu RK; Nery PB; Lellouche N; Connolly SJ; Sapp J; Essebag V
Eur Heart J; 2018 Nov; 39(44):3973-3979. PubMed ID: 30462279
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation.
Michaud GF; Pelosi F; Noble MD; Knight BP; Morady F; Strickberger SA
J Am Coll Cardiol; 2000 Jun; 35(7):1915-8. PubMed ID: 10841243
[TBL] [Abstract][Full Text] [Related]
13. Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I).
Turagam MK; Nagarajan DV; Bartus K; Makkar A; Swarup V
J Interv Card Electrophysiol; 2017 Aug; 49(2):197-204. PubMed ID: 28413854
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of pocket hematoma after cardiac device implantation and replacement.
Ferretto S; Mattesi G; Migliore F; Susana A; De Lazzari M; Iliceto S; Leoni L; Bertaglia E
J Cardiovasc Med (Hagerstown); 2020 Feb; 21(2):123-127. PubMed ID: 31789710
[TBL] [Abstract][Full Text] [Related]
15. [Continued oral anticoagulation during cardiac pacing: the BRUISE CONTROL study].
Proietti R; Birnie DH; Healey JS; Verma A; Essebag V
G Ital Cardiol (Rome); 2013 Nov; 14(11):724-5. PubMed ID: 24326634
[No Abstract] [Full Text] [Related]
16. Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation.
Chen HC; Chen YL; Guo BF; Tsai TH; Chang JP; Pan KL; Lin YS; Chen MC
Can J Cardiol; 2013 Sep; 29(9):1110-7. PubMed ID: 23474139
[TBL] [Abstract][Full Text] [Related]
17. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.
Thal S; Moukabary T; Boyella R; Shanmugasundaram M; Pierce MK; Thai H; Goldman S
Pacing Clin Electrophysiol; 2010 Apr; 33(4):385-8. PubMed ID: 20059711
[TBL] [Abstract][Full Text] [Related]
18. Risk of hematoma complications after device implant in the clopidogrel era.
Kutinsky IB; Jarandilla R; Jewett M; Haines DE
Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):312-8. PubMed ID: 20558847
[TBL] [Abstract][Full Text] [Related]
19. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
Tompkins C; Cheng A; Dalal D; Brinker JA; Leng CT; Marine JE; Nazarian S; Spragg DD; Sinha S; Halperin H; Tomaselli GF; Berger RD; Calkins H; Henrikson CA
J Am Coll Cardiol; 2010 May; 55(21):2376-82. PubMed ID: 20488310
[TBL] [Abstract][Full Text] [Related]
20. Cardiac rhythm device surgery with uninterrupted oral anticoagulation.
Tyagi G; Pai SM; Pai RG
Future Cardiol; 2013 Nov; 9(6):763-6. PubMed ID: 24180532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
